{"id":"W3035208766","doi":"10.1158/1078-0432.ccr-20-0621","title":"Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":172,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Sierra Oncology; Australian Government; Eisai; BeiGene; Sanofi; Clovis Oncology; AstraZeneca; Bristol-Myers Squibb; Amgen","keywords":"Nivolumab; Ipilimumab; Medicine; Clinical endpoint; Internal medicine; Clinical trial; Response Evaluation Criteria in Solid Tumors; Progressive disease; Neuroendocrine tumors; Immunotherapy; Gastroenterology; Oncology; Phases of clinical research; Surgery; Cancer; Chemotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001470422,0.0002441928,0.001704492,0.0003599932,0.00009303367,0.0000185419,0.0006137465,0.00003114099,0.0001105953],"category_scores_gemma":[0.006608485,0.0001614958,0.0005345456,0.002909325,0.001596703,0.0001366916,0.0003280425,0.001402714,7.528396e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001749352,"about_ca_system_score_gemma":0.001408621,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007027938,"about_ca_topic_score_gemma":0.00122785,"domain_scores_codex":[0.9937112,0.001153005,0.001866436,0.0009472796,0.001491744,0.000830356],"domain_scores_gemma":[0.9940512,0.003204938,0.0004603309,0.0008381965,0.0009859144,0.000459474],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.2936655,0.0007833738,0.6875437,0.0002876415,0.0005891466,0.00006400538,0.00006950834,0.0001108508,0.000108332,0.00001699664,0.000290285,0.01647068],"study_design_scores_gemma":[0.183851,0.02587579,0.7853873,0.0002820395,0.0003110554,0.000002682378,0.0001958816,0.0008119371,0.0006916141,0.00003996356,0.002360493,0.0001901549],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9909365,0.0007371737,0.000007564159,0.00373121,0.0001459086,0.004184535,0.0001975754,0.0000170141,0.00004257075],"genre_scores_gemma":[0.9970787,0.001534423,0.0001724321,0.0004583442,0.0001833995,0.0004029752,0.00002134764,0.00005643931,0.000091898],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1098145,"threshold_uncertainty_score":0.7911451,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1458014106400074,"score_gpt":0.4961921606803399,"score_spread":0.3503907500403325,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}